Purpose. The direct rapid antibiotic susceptibility test (dRAST), based on analysing changes in bacterial micro-colonies under antibiotic conditions, detects antibiotic resistance within 6 h of direct smear examination results. This study aimed to assess the accuracy of dRAST and evaluate its potential usefulness for improving selection of appropriate antibiotic in real clinical practice settings.
INTRODUCTION
Bloodstream infection, which can progress to severe sepsis and septic shock, is a common cause of morbidity and mortality. One study showed that mortality increased in septic shock patients for each hour of delay in administration of antibiotics after shock onset [1] . To increase the survival rate of patients with sepsis, early administration of appropriate antibiotics is important; however, the rate of treatment failure increases in an environment where there is a high likelihood of acquisition of resistant strains arising from the frequent misuse of antibiotics [2] . Approximately 25 000 people in Europe and 23 000 people in the United States die every year because of infection caused by antibiotic-resistant bacteria [3] .
Because more than 24-48 h is usually needed to confirm antibiotic susceptibility from the time of a positive blood culture result, administering the appropriate antibiotics in a timely way is difficult. Furthermore, initial empirical antibiotic treatments are sometimes inadequate in that they are either ineffective treatment or unnecessary broad-spectrum treatment. Given these limitations, several attempts have been made to develop rapid and accurate antibiotic susceptibility testing (AST) [4] , which not only shortens the time for susceptibility results but also decreases mortality rates and healthcare costs [5, 6] .
A novel AST, the direct rapid antibiotic susceptibility test (dRAST, QuantaMatrix Inc.), detects antibiotic resistance within 6 h after direct smear examination (DSE) results become available, by analysing the change in single bacterial cell morphology under various antibiotic conditions [7] . In a previous study, we showed the excellent performance of this technique with rates of 91.11 % categorical agreement, 1.45 % very major errors (VMEs), 2.72 % major errors (MEs) and 6.69 % minor errors (mEs) [8] . Thus, dRAST would enable clinicians to select the most appropriate antibiotics and overcome the time limitations of conventional AST. However, it is also important that the rapidity and accuracy of antibiotic selection be maintained for antibiotics that are often chosen for treatment in clinical situations such as sepsis. Before applying dRAST in such situations, it is necessary to know how it demonstrates clinical accuracy with certain antibiotics, such as b-lactams or glycopeptides, that are preferred in sepsis patients. Little is known about the degree of clinical utility of dRAST in this respect.
In this study, we aimed to assess the accuracy of dRAST and evaluate its potential usefulness for improving the selection of appropriate antibiotics in real clinical practice settings.
METHODS

Study population
This retrospective study was conducted at a tertiary medical centre with 1300 beds, Seoul National University Hospital in South Korea. Patients who were admitted from June 2015 to December 2015 and were 18 years of age or older with a positive blood culture were included for analysis. We excluded patients who were transferred with a previous positive blood culture or those who died within 24 h of the positive blood culture. Fig. 1 shows the study design. During the study period, the types of blood culture bottles used were BACTEC Plus Aerobic/F and Anaerobic/F culture bottles and BacT/Alert FA Plus and SN bottles, which were processed using a BAC-TEC FX automated incubation system (Becton Dickinson Company, NJ) and a BacT/Alert 3D system (bioM erieux Inc., Marcy l'Etoile, France), respectively. The positive blood cultures were processed by current microbiology analysers (VITEK2, bioM erieux and MicroScan, Beckman Coulter).
Data collection
Gram-negative strains were tested for identification and antibiotic susceptibility by VITEK2, and Gram-positive strains by Microscan. Concurrently, the aliquots of positive blood culture fluid were processed for evaluation using both the broth microdilution (BMD) test, regarded as the standard reference method [9] , and dRAST. Because dRAST could not identify the species of bacterial organism, a MALDI-TOF Biotyper and Sepsityper kit from Bruker (Billerica, MA), which can quickly and accurately identify species [4, 10] , was utilized in an aliquot of positive blood culture fluid simultaneously with dRAST. In dRAST, after the identification of Gram-negative and -positive bacteria by direct smear examination, 10 µl of aliquot was diluted 100-fold with cation-adjusted Mueller-Hinton broth (CAMHB, BD Biosciences, CA), and 300 µl of the diluted sample was mixed with 900 µl of liquid-state 0.5 % agarose at 37-40 C at a 1 : 3 vol. ratio for immobilization. Ten microlitres of the agarose mixture was loaded onto 96-well format microfluidic chips containing freeze-dried antibiotic agents. After this process, 100 µl of culture medium (CAMHB) was loaded onto the chips and we rehydrated the freeze-dried antibiotic agent. Immobilized bacterial cells were then exposed to the antibiotic agents and morphological analysis started by time-lapse imaging at 0, 2, 4 and 6 h [8] . Gram-negative strains were tested for susceptibility to amikacin, amoxicillin/clavulanic acid, cefotaxime, ceftazidime, cefepime, colistin, fosfomycin, gentamicin, imipenem, meropenem, piperacillin, piperacillin/tazobactam, ticarcillin, ticarcillin/clavulanic acid, tobramycin and trimethoprim/sulfamethoxazole. Gram-positive strains were tested for susceptibility to ampicillin, ciprofloxacin, levofloxacin, erythromycin, gentamicin, imipenem, linezolid, oxacillin, penicillin, tetracycline, trimethoprim/sulfamethoxazole and vancomycin. Susceptibility was determined by whether the number of bacterial micro-colonies that had increased at 6 h. dRAST results were interpreted with minimal inhibitory concentration criteria from the Clinical and Laboratory Standards Institute and were reported as susceptible, intermediate or resistant. All cases with a low MALDI score (<1.7) were excluded from analysis due to the low credibility of data.
Only results from the current microbiology analysers were reported to the attending physician and surgeon for clinical decision making. Even when Staphylococcus aureus, Enterococcus spp. and Gram-negative rod strains were isolated from only one blood culture bottle, these were considered clinically significant. For coagulase-negative staphylococci, when antibiotics had not been initiated, or had been initiated in response to positive Gram staining results but stopped within 48 h after identification, the isolate from only one of the blood culture bottles was considered a contaminant and clinically insignificant. When antibiotics were continued for more than 48 h after identification, the isolate was considered to have clinical significance. We collected information on all antibiotics prescribed to patients, the type of infection classified according to the US Centers for Disease Control and Prevention guidelines [11] , blood culture collection time and time to reporting of the Gram stain result, species identification and susceptibility. The clinical severity of each patient was also investigated by the Pitt bactaeremia score based on the day of the index culture [12] . Other demographic and clinical characteristics, including underlying co-morbidity, were also obtained from the electronic medical record (EMR).
Evaluation of the accuracy and potential clinical impact of dRAST
We evaluated the accuracy of dRAST by comparing the treatments indicated respectively by the results of dRAST and BMD. Appropriate treatments according to dRAST were determined by an infection specialist, preceding the decision for treatments according to BMD by the same person.
For evaluation of potential clinical impact by introduction of dRAST, we analysed how these patients were treated with current microbiology analysers and calculated how many patients could have benefitted if the dRAST results had been made available to the attending clinicians. We classified antibiotic therapy as optimal targeted, broadspectrum, suboptimal or ineffective on the basis of the species isolated and the organism's susceptibility to antibiotics [13] [14] [15] . Treatment classes were defined as follows: optimal targeted treatment, administration of antibiotics to which the organisms were susceptible and considered as the most effective and narrowest spectrum treatment; broad-spectrum treatment, administration of antibiotics to which organisms were susceptible and effective but that had broad-spectrum activity requiring de-escalation; suboptimal treatment, administration of antibiotics to which organisms were susceptible and that were considered inferior to first-line antibiotics (e.g. vancomycin for methicillin-susceptible Staphylococcus aureus); and ineffective treatment, administration of antibiotics to which organisms had intermediate susceptibility or were resistant, or no treatment at all. Then, we observed how this treatment group changed after current microbiology analysers results were reported.
Statistical analyses
Data are presented as mean values and ranges for continuous variables or numbers with percentages for categorical variables. The difference in average time from blood culture positive detection to reporting of AST results between dRAST and current AST was analysed using the Wilcoxon signed rank test because of non-parametric data. All statistical tests were performed using SPSS2 statistical software (Version 18.0, SPSS. Inc., Chicago, IL).
RESULTS
Baseline characteristics of the study population Among the 124 included patients with bactearemia, five cases with low MALDI score were excluded from the analysis. The remaining 119 patients with bacteraemia, and their blood culture collections, were included for analysis. The clinical and demographical characteristics of patients are shown in Table 1 . Fifty-five percent were male and mean age was 63.0±16.2 [standard deviation (SD)] years (range: 18-95 years). The mean time from blood culture collection to positive detection was 13.3±7.5 h (range: 2.1-57.2). Biliary tract infection was the most common type of infection (19.3 %), followed by primary bacteraemia with no known portal of entry (17.6 %), catheter-associated infection (16.8 %) and urinary tract infection (15.1 %). A total of 27 % of patients presented with septic shock at the time of blood culture collection. The median Pitt bacteraemia score was 1 (range: 0-8) and patients with 4 points or more comprised 12.7 %.
Of the 119 patients (Table 2) , Gram-positive bacteria were detected in 52 (45.1 %) and Gram-negative bacteria in 67 (54.8 %). Of these isolates, vancomycin-resistant Enterococcus (VRE) spp. (n=8), methicillin-resistant Staphylococcus aureus (MRSA) (n=7), extended-spectrum b-lactamase (ESBL)-positive Enterobacteriaceae (n=18), carbapenemresistant Pseudomonas aeruginosa (n=5) and carbapenem- resistant Acinetobacter baumannii (n=4) were included. There were two case of mixed infection. One case presented with ESBL-negative E. coli and ESBL-positive E. coli, while another presented with Aeromonas spp. and ESBL-negative E. coli.
Comparison of antibiotic treatments to be prescribed according to dRAST and BMD test results
We compared the antibiotics prescribed according to the BMD test results with those that would have been prescribed based on dRAST. Of 119 patients, four cases had discordant results (Table 3) . For 49/52 (94.2 %) patients with Gram-positive bacteraemia, the antibiotics that would have been prescribed in accordance with dRAST results were identical to those prescribed based on BMD test results. There were two oxacillin VMEs with MRSA and one vancomycin VME with VRE. For 66/67 (98.5 %) patients with Gram-negative bacteraemia, antibiotics that would have been prescribed in accordance with dRAST results were the same as those prescribed in accordance with the BMD test. One discordant case was a mixed infection with ESBL-and -positive E. coli. There were no MEs or mEs leading to unnecessary broad-spectrum antibiotic use. There were MEs for a third-generation cephalosporin against Serratia marcescens and for a fourth-generation cephalosporin against E. coli, but those errors did not affect antibiotic selection or lead to unnecessary broad-spectrum antibiotic use. Fig. 2 shows the progress of clinical treatment in 119 patients. After DSE results were reported, 52 (43.6 %) patients received optimal targeted treatment and 33 (27.7 %) received broad-spectrum treatment. On the other hand, 29 (24.3 %) received ineffective treatment and 5 (4.2 %) had suboptimal treatment. After the final identification and susceptibility results were reported in the EMR, 22 (64.7 %) of 34 patients under ineffective or suboptimal treatment received optimal targeted treatment. Except for three VME cases, 19 (55.9 %) of the 34 patients could have received optimal targeted treatment earlier with the dRAST results. Among the 33 patients with broad-spectrum treatment following the disclosure of DES results, antibiotic de-escalation was performed in 27 (81.8 %) after the full phenotypic results were known. Of these 27 patients, empirical antibiotics used were carbapenem (n=17), vancomycin (n=8) and piperacillin/tazobactam (n=2).
Potential impact of dRAST on administration of optimal targeted treatment
The average turnaround time for dRAST and the current microbiology analyser with VITEK2 and Microscan from blood culture positive detection was 14.3±4.2 and 64.5 ±22.3 h, respectively (P<0.001) (Fig. 3) . For Gram-negative strains, the average turnaround time for the two methods was 14.4±3.8 and 64.4±20.8 h, respectively (P<0.001). For Gram-positive strains, the average turnaround time for the two methods was 14.2±4.8 and 64.6±24.2 h, respectively (P<0.001).
DISCUSSION
We evaluated the accuracy of dRAST and its potential to improve the selection of appropriate antibiotics in realworld clinical practice. With the proper use of dRAST by the clinicians, better treatment could have been provided to at least 19 (55.9 %) of the 34 patients administered ineffective or suboptimal treatment, and to 27 (81.8 %) of the 33 patients with unnecessary broad-spectrum treatment, in the early period of bacteraemia.
With current microbiology analysers such as VITEK2 and MicroScan, AST should be initiated after an additional subculture step that increases the time required to obtain the full test results. Because of the long turnaround time, initial antibiotic treatments of choice are often based on the physician's experience and educated guesswork [16] . However, dRAST does not require the subculture step and only a change in bacterial cell morphology is needed to determine susceptibility results [7, 8] . Therefore, the time from blood sample collection to obtaining the susceptibility results can be reduced by approximately 1 to 2 days and the duration of empirical treatment can be reduced. Reducing this time is especially important because the proportion of major antibiotic-resistant pathogens, such as ESBL-positive E. coli and K. pneumoniae, carbapenem-resistant P. aeruginosa and VRE and MRSA, is increasing [17] [18] [19] . Patients who have been on ineffective treatment due to resistant organisms not covered by empirical therapy will receive more rapid optimal treatment. Furthermore more rapid results help the clinical practitioner reduce antibiotic administration, making for better antibiotic stewardship.
For Gram-negative organisms, there was no VME with commonly used antibiotics such as b-lactam/b-lactamase inhibitors, broad-spectrum cephalosporins and carbapenem. In mixed infection with ESBL-negative and -positive E. coli, although the BMD test identified the bacteria as susceptible to broad-spectrum cephalosporin, an intermediate or resistant result was reported by dRAST. These findings suggest that dRAST may be of great help in the early stage of Gram-negative bacterial infection. For Gram-positive organisms, most errors involve the use of antibiotics that are generally not considered the primary choice of agent; however, two VMEs for oxacillin were found in MRSA, and one VME for vancomycin was found in VRE. There were no MEs for oxacillin and vancomycin. These results are thought to arise from variation in bacterial growth cycles among isolates. If those bacteria were actually resistant to certain antibiotics and the bacterial growth cycle was in the lag phase, the test results could be incorrectly reported as susceptible. Because analysing changes in bacterial cell morphology requires 6 h for Gram-positive strains in dRAST [8] , bacterial cell division may have been observed after 6 h. Indeed, we further followed up these three isolates showing VMEs and observed an increase in the number of microcolonies at 8 h, and reported the initial susceptibility result as resistant. Because the total turnaround time to obtain susceptibility results for antibiotics can be adjusted, these unfavourable results can be addressed and the accuracy of the test would be increased. Even if we increase Grampositive strain testing time from 6 to 8 h for accuracy, the advantage of not requiring a subculture step is still valid.
By assessing the potential clinical impact of dRAST, we showed the potential of its effect on antibiotic misuse, in terms of both earlier optimal antibiotic choice and deescalation of broad-spectrum antibiotic use. Although there were some MEs and mEs, these errors did not induce incorrect antibiotic selection decisions. Therefore, 27/33 (81.8 %) cases of de-escalation suggest the potential effect of dRAST on decreasing unnecessary broad-spectrum antibiotic exposure, including that to carbapenem. A previous study reported that brief exposure to imipenem, for just 1-3 days, could increase the risk of imipenem resistance by fivefold [20] . We consider that dRAST would help alleviate this clinical problem.
This study has several limitations. First, the design was retrospective and improvement in clinical outcomes, such as patient mortality, length of hospital stay and cost, could not be measured. Second, this study was conducted in a single centre. Because each hospital has a different bacterial ecology and antibiotic resistance, there will be some variation in diagnostic and treatment systems. To validate the usefulness of dRAST, additional multi-centre studies are needed. Third, the numbers of bacterial strains at species level tested here using dRAST may be inadequate. Further study is needed with more bacterial species. Finally, the results of this study on appropriate antibiotic selection are based on simulation and the clinical impact of this testing on these selections may depend on the clinical practitioner and lab working time, because a normal working day in most labs is not 24 h. The results should be confirmed in a prospective investigation; however, they will have significance in helping clarify benefits available before the actual introduction of the test.
In summary, the introduction of dRAST could increase the use of optimal antibiotics and reduce that of unnecessary broad-spectrum antibiotics in the early period of bacteraemia. 
